佐力药业 (300181)

1. Key Indicators

• Total Shares(W): 70138.73
• Circulating A-Shares(W): 60291.09
• Earnings Per Share(RMB): 0.7271
• Net Assets Per Share(RMB): 4.4442
• Operating Revenue(W RMB): 227971.34
• Total Profit(W RMB): 61076.03
• Net Profit Attributable to Parent(W RMB): 50997.45
• Net Profit Growth Rate(%): 21.00
• Weighted Return on Equity(%): 18.05
• Operating Cash Flow Per Share(RMB): 0.3790
• Undistributed Profit Per Share(RMB): 1.3413
• Capital Reserve Per Share(RMB): 1.6091

---

2. Main Business

The main business covers:

• Research, development, production, and sales of pharmaceuticals.

---

3. Company Basic Information

• Company Name: Zhejiang Jolly Pharmaceutical Co., Ltd.
• Listing Date: 2011-02-22
• Industry: Pharmaceutical Manufacturing
• Address: No. 388 Zhiyuan North Road, Fuxi Street, Deqing County, Zhejiang Province, China.
• Website: www.jolly.com.cn, www.zuoli.com
• Company Profile: The company was established on January 28, 2000, approved by the Zhejiang Provincial Government Securities Committee (Document No. ZJZQ [2000]3). It was restructured from the former Zhejiang Jolly Pharmaceutical Co., Ltd. and jointly funded by four legal entities including Shanghai Industrial United Group Co., Ltd., Zhejiang Beihu Group Co., Ltd., Hangzhou University Deqing High-Tech Industrial Development Corporation, Zhejiang Rongyi Industrial Development Co., Ltd., and a natural person, Ms. Chen Wanru. The registered capital was 120 million RMB, with a total share capital of 120 million shares. The promoters subscribed to shares with their respective assessed net assets of 75 million RMB and cash of 45 million RMB from the former company. On January 28, 2000, the company completed its industrial and commercial registration at the Zhejiang Provincial Administration for Industry and Commerce, with registration number 3300001006402. In April 2008, the company implemented a 2:1 share consolidation, reducing the total share capital from 120 million shares to 60 million shares. The registered capital before this issuance was 60 million RMB. During the 2008 annual industrial and commercial inspection, the registration number was upgraded to 330000000017843.

---

4. Top 10 Circulating Shareholders

Rank	Institution Name	Institution Type	Shares Held (W)	Percentage Held (%)
1	National Social Security Fund 403 Portfolio	Social Security Fund	1049.05	1.74
2	China Europe Fund - China Life Insurance Co., Ltd. - Participating Insurance - China Europe Fund China Life Shares Balanced Equity Portfolio Single Asset Management Plan (Available for Sale)	Asset Management Plan	961.47	1.59
3	China Europe Fund - China Life Insurance Co., Ltd. - Traditional Insurance - China Europe Fund China Life Shares Balanced Equity Traditional Available-for-Sale Single Asset Management Plan	Asset Management Plan	940.43	1.56
4	Yinhua CSI Innovation Pharmaceutical Industry Exchange Traded Open-End Index Securities Investment Fund	Fund	685.49	1.14
5	Zhejiang Jolly Pharmaceutical Co., Ltd. - 2024 Employee Stock Ownership Plan	Asset Management Plan	672.50	1.12
6	Southern CSI 1000 Exchange Traded Open-End Index Securities Investment Fund	Fund	641.72	1.06
7	China Universal CSI Traditional Chinese Medicine Exchange Traded Open-End Index Securities Investment Fund	Fund	437.01	0.72
8	Penghua CSI Traditional Chinese Medicine Exchange Traded Open-End Index Securities Investment Fund	Fund	167.29	0.28
9	Manulife Dividend Pioneer Hybrid Securities Investment Fund Class A	Fund	14.19	0.02
10	Zheshang Huijin Stable Growth One-Year Holding Period Hybrid Securities Investment Fund	Fund	14.14	0.02

---

5. Concept Sectors

• Gene Concept
• Immunotherapy
• Innovative Drugs
• Margin Trading & Securities Lending
• High-Performance Stocks
• Intensive Research
• Issuance of Convertible Bonds
• High-Dividend Stocks

---

Remarks

• Data update date: 2026-01-01
• Data source: Public Market Information